Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Urinary Bladder Neoplasms 4Urothelial Carcinoma of the Bladder 1Squamous Cell Carcinoma of Head and Neck 1Non-Muscle Invasive Bladder Urothelial Carcinoma 1Non-Muscle Invasive Bladder Neoplasms 1Neuroblastoma 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Laryngeal Neoplasms 1Ganglioneuroblastoma 1Carcinoma 1Brain Neoplasms 1

Interventions

Radiosurgery 7Temozolomide 6pembrolizumab 4Magnetic Resonance Spectroscopy 4Bevacizumab 4Specimen Handling 3Nivolumab 3abemaciclib 2Watchful Waiting 2Surveys and Questionnaires 2Receptors, Interleukin-8B 2Radiation 2Mental Status and Dementia Tests 2Memantine 2Ipilimumab 2Biopsy 2vorasidenib 1sotorasib 1sapanisertib 1ribociclib 1pertuzumab 1osimertinib 1lenvatinib 1fluciclovine F-18 1entrectinib 1encorafenib 1elacestrant 1dexamethasone acetate 1dexamethasone 21-phosphate 1brivaracetam 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × Transurethral Resection of Bladder × 30 days × Clear all
NCT06914479 2026-05-27

Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors

University of Michigan Rogel Cancer Center

Phase 1 Recruiting
11 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡